

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9995)

ANNOUNCEMENT ON THE RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of RemeGen Co., Ltd.* (the “**Company**”) has recently received the written resignation from Dr. Ma Lan, an independent non-executive Director. Dr. Ma Lan has tendered her resignation as an independent non-executive Director of the Board and as a member of the nomination committee and of the strategy committee in accordance with the relevant regulations governing part-time engagement of academicians of the Chinese Academy of Sciences (中國科學院).

Given that Dr. Ma Lan’s resignation would cause the number of independent non-executive Directors falling below one-third of the Board, in accordance with the relevant provisions under the Company Law of the People’s Republic of China (the “**PRC**”) (《中華人民共和國公司法》), the PRC’s Measures for the Management of Independent Directors of Listed Companies (《上市公司獨立董事管理辦法》), the Rules Governing the Listing of Stocks on the Science and Technology Innovation Board of Shanghai Stock Exchange (《上海證券交易所科創板股票上市規則》), the Self-Regulatory Guideline for Listed Companies on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 — Regularization of Operation (《上海證券交易所科創板上市公司自律監管指引第 1 號——規範運作》), the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, her resignation shall take effect on the date on which a new independent non-executive Director is appointed and takes office. Prior to that, Dr. Ma Lan shall continue to perform her duties in accordance with the requirements of relevant laws, regulations and the articles of association of the Company. The Company will complete the election of an independent non-executive Director to fill the vacancy in accordance with relevant regulations as soon as practicable.

Dr. Ma Lan has confirmed that she has no disagreement with the Company and the Board, and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company. As of the date of this announcement, Dr. Ma Lan does not directly or indirectly hold any shares of the Company, and there are no outstanding commitments that should have been fulfilled.

During her tenure of service as an independent non-executive Director of the Company, Dr. Ma Lan was diligent, responsible and objectively independent, and played an active and effective role in promoting the Company's standardized operations. The Company and the Board would like to express their sincere gratitude to Dr. Ma Lan for her contributions to the Company and the Board during her tenure of service.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive director

Yantai, The People's Republic of China
November 14, 2024

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive directors.

* *For identification purpose only*